Prostate-specific antigen (PSA) is a marker specific to the prostate gland, and it is, therefore, possible to observe an increase in PSA above 4 ng/mL in cases of benign prostatic hypertrophy and cancer. But according to studies, a very high PSA level is most likely synonymous with metastatic prostate cancer. Our rare case concerns the management of a localized prostatic adenocarcinoma despite a very high PSA level of over 3000 ng/mL, with an enormous volume of prostate without invasion or distant metastasis. A very high PSA level can probably be a sign of metastatic prostatic adenocarcinoma, but not necessarily.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407271PMC
http://dx.doi.org/10.1016/j.radcr.2023.07.022DOI Listing

Publication Analysis

Top Keywords

psa level
16
prostatic adenocarcinoma
12
high psa
12
management localized
8
localized prostatic
8
adenocarcinoma despite
8
despite high
8
psa
7
prostatic
4
high
4

Similar Publications

Background: Sesame allergy (SA) is a growing concern because of its association with severe reactions and the limited knowledge of long-term outcomes.

Objective: This retrospective study aimed to identify the risk factors influencing persistent SA (PSA) in children to improve management and select suitable candidates for oral immunotherapy (OIT).

Methods: We analyzed the electronic medical records of 84 children with confirmed SA, as defined by consistent clinical reactions and immunoglobulin E (IgE)-mediated sensitization.

View Article and Find Full Text PDF

To investigate the potential of an MRI-based radiomic model in distinguishing malignant prostate cancer (PCa) nodules from benign prostatic hyperplasia (BPH)-, as well as determining the incremental value of radiomic features to clinical variables, such as prostate-specific antigen (PSA) level and Prostate Imaging Reporting and Data System (PI-RADS) score. A restrospective analysis was performed on a total of 251 patients (training cohort, n = 119; internal validation cohort, n = 52; and external validation cohort, n = 80) with prostatic nodules who underwent biparametric MRI at two hospitals between January 2018 and December 2020. A total of 1130 radiomic features were extracted from each MRI sequence, including shape-based features, gray-level histogram-based features, texture features, and wavelet features.

View Article and Find Full Text PDF

An Automatic Deep-Radiomics Framework for Prostate Cancer Diagnosis and Stratification in Patients with Serum Prostate-Specific Antigen of 4.0-10.0 ng/mL: A Multicenter Retrospective Study.

Acad Radiol

January 2025

Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China (B.Z., F.M., X.S., S.L., Q.W.); Department of Urology, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, Guangdong 510080, China (Q.W.). Electronic address:

Rationale And Objectives: To develop an automatic deep-radiomics framework that diagnoses and stratifies prostate cancer in patients with prostate-specific antigen (PSA) levels between 4 and 10 ng/mL.

Materials And Methods: A total of 1124 patients with histological results and PSA levels between 4 and 10 ng/mL were enrolled from one public dataset and two local institutions. An nnUNet was trained for prostate masks, and a feature extraction module identified suspicious lesion masks.

View Article and Find Full Text PDF

Objective: In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to determine effective cutoff scores for the Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) based on disease activity measures in patients with PsA.
  • Using data from the ReFlaP study, researchers analyzed scores to define disease states such as remission and varying impact levels, employing statistical methods to establish these cutoffs.
  • Results indicated that the PsAID12 score had high diagnostic performance against established benchmarks, but further validation and expert consensus are needed to confirm the proposed cutoffs for clinical use.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!